nodes	percent_of_prediction	percent_of_DWPC	metapath
Naproxen—Ibuprofen—Melphalan—breast cancer	0.203	1	CrCrCtD
Naproxen—PTGS1—breast cancer	0.112	0.481	CbGaD
Naproxen—PTGS2—breast cancer	0.0643	0.275	CbGaD
Naproxen—ALB—breast cancer	0.0573	0.245	CbGaD
Naproxen—SLCO1A2—Chlorambucil—breast cancer	0.0454	0.146	CbGbCtD
Naproxen—AKR1C3—Doxorubicin—breast cancer	0.0424	0.136	CbGbCtD
Naproxen—UGT2B7—Epirubicin—breast cancer	0.0249	0.08	CbGbCtD
Naproxen—UGT1A1—Irinotecan—breast cancer	0.0209	0.0673	CbGbCtD
Naproxen—CYP1A2—Anastrozole—breast cancer	0.0185	0.0595	CbGbCtD
Naproxen—CYP1A2—Toremifene—breast cancer	0.0169	0.0544	CbGbCtD
Naproxen—CYP2C9—Anastrozole—breast cancer	0.0167	0.0536	CbGbCtD
Naproxen—CYP2C8—Lapatinib—breast cancer	0.016	0.0513	CbGbCtD
Naproxen—CYP2C9—Idarubicin—breast cancer	0.0126	0.0406	CbGbCtD
Naproxen—CYP2C8—Raloxifene—breast cancer	0.0121	0.0389	CbGbCtD
Naproxen—SLCO1A2—Methotrexate—breast cancer	0.00813	0.0261	CbGbCtD
Naproxen—CYP2C8—Tamoxifen—breast cancer	0.00799	0.0257	CbGbCtD
Naproxen—ALB—Irinotecan—breast cancer	0.00794	0.0255	CbGbCtD
Naproxen—ALB—Fluorouracil—breast cancer	0.00762	0.0245	CbGbCtD
Naproxen—CYP2C9—Capecitabine—breast cancer	0.00693	0.0223	CbGbCtD
Naproxen—CYP2C8—Paclitaxel—breast cancer	0.00622	0.02	CbGbCtD
Naproxen—CYP1A2—Tamoxifen—breast cancer	0.00619	0.0199	CbGbCtD
Naproxen—CYP2C8—Fluorouracil—breast cancer	0.00589	0.0189	CbGbCtD
Naproxen—CYP2C9—Tamoxifen—breast cancer	0.00557	0.0179	CbGbCtD
Naproxen—SLC22A6—Methotrexate—breast cancer	0.00493	0.0159	CbGbCtD
Naproxen—CYP1A2—Fluorouracil—breast cancer	0.00456	0.0146	CbGbCtD
Naproxen—CYP2C9—Paclitaxel—breast cancer	0.00434	0.0139	CbGbCtD
Naproxen—ALB—Methotrexate—breast cancer	0.0042	0.0135	CbGbCtD
Naproxen—CYP2C9—Fluorouracil—breast cancer	0.00411	0.0132	CbGbCtD
Naproxen—AKR1C3—nipple—breast cancer	0.000875	0.0647	CbGeAlD
Naproxen—AKR1C3—Vincristine—Vinorelbine—breast cancer	0.000775	0.384	CbGdCrCtD
Naproxen—ALB—mammary gland—breast cancer	0.000657	0.0486	CbGeAlD
Naproxen—AKR1C3—Vinblastine—Vinorelbine—breast cancer	0.000623	0.309	CbGdCrCtD
Naproxen—AKR1C3—Vincristine—Vinblastine—breast cancer	0.000619	0.307	CbGdCrCtD
Naproxen—AKR1C3—endometrium—breast cancer	0.000528	0.0391	CbGeAlD
Naproxen—AKR1C3—uterus—breast cancer	0.000487	0.036	CbGeAlD
Naproxen—AKR1C3—pituitary gland—breast cancer	0.000478	0.0354	CbGeAlD
Naproxen—AKR1C3—adipose tissue—breast cancer	0.000476	0.0352	CbGeAlD
Naproxen—UGT2B7—female reproductive system—breast cancer	0.000475	0.0351	CbGeAlD
Naproxen—CYP2C8—mammary gland—breast cancer	0.000461	0.0342	CbGeAlD
Naproxen—AKR1C3—adrenal gland—breast cancer	0.000427	0.0316	CbGeAlD
Naproxen—AKR1C3—bone marrow—breast cancer	0.000413	0.0306	CbGeAlD
Naproxen—CYP2C9—mammary gland—breast cancer	0.00041	0.0303	CbGeAlD
Naproxen—UGT2B7—endocrine gland—breast cancer	0.000402	0.0297	CbGeAlD
Naproxen—AKR1C3—female gonad—breast cancer	0.000398	0.0295	CbGeAlD
Naproxen—CYP1A2—nipple—breast cancer	0.000357	0.0264	CbGeAlD
Naproxen—UGT1A1—endocrine gland—breast cancer	0.000341	0.0253	CbGeAlD
Naproxen—PTGS1—nipple—breast cancer	0.00031	0.0229	CbGeAlD
Naproxen—ALB—adrenal gland—breast cancer	0.000265	0.0196	CbGeAlD
Naproxen—AKR1C3—lymph node—breast cancer	0.000256	0.0189	CbGeAlD
Naproxen—PTGS2—embryo—breast cancer	0.000244	0.0181	CbGeAlD
Naproxen—Indomethacin—SLCO1B1—breast cancer	0.000237	0.0762	CrCbGaD
Naproxen—Nabumetone—PTGS1—breast cancer	0.000235	0.0758	CrCbGaD
Naproxen—SLCO1A2—endocrine gland—breast cancer	0.000231	0.0171	CbGeAlD
Naproxen—CYP2C8—endometrium—breast cancer	0.00023	0.0171	CbGeAlD
Naproxen—Carprofen—PTGS1—breast cancer	0.000224	0.0723	CrCbGaD
Naproxen—CYP2C8—pituitary gland—breast cancer	0.000209	0.0154	CbGeAlD
Naproxen—PTGS1—epithelium—breast cancer	0.000208	0.0154	CbGeAlD
Naproxen—PTGS2—epithelium—breast cancer	0.000199	0.0147	CbGeAlD
Naproxen—PTGS1—skin of body—breast cancer	0.000198	0.0147	CbGeAlD
Naproxen—Indomethacin—ABCC1—breast cancer	0.000195	0.0629	CrCbGaD
Naproxen—CYP2C8—female reproductive system—breast cancer	0.000191	0.0141	CbGeAlD
Naproxen—PTGS2—skin of body—breast cancer	0.000189	0.014	CbGeAlD
Naproxen—PTGS1—endometrium—breast cancer	0.000187	0.0138	CbGeAlD
Naproxen—PTGS2—endometrium—breast cancer	0.000179	0.0132	CbGeAlD
Naproxen—Indomethacin—CXCL8—breast cancer	0.000173	0.0557	CrCbGaD
Naproxen—PTGS1—uterus—breast cancer	0.000172	0.0127	CbGeAlD
Naproxen—Ibuprofen—BCL2—breast cancer	0.00017	0.0547	CrCbGaD
Naproxen—CYP2C9—female reproductive system—breast cancer	0.00017	0.0126	CbGeAlD
Naproxen—PTGS1—pituitary gland—breast cancer	0.000169	0.0125	CbGeAlD
Naproxen—PTGS1—adipose tissue—breast cancer	0.000168	0.0125	CbGeAlD
Naproxen—PTGS2—uterus—breast cancer	0.000165	0.0122	CbGeAlD
Naproxen—PTGS2—pituitary gland—breast cancer	0.000162	0.012	CbGeAlD
Naproxen—CYP2C8—endocrine gland—breast cancer	0.000162	0.012	CbGeAlD
Naproxen—PTGS2—adipose tissue—breast cancer	0.000161	0.0119	CbGeAlD
Naproxen—ALB—lymph node—breast cancer	0.000159	0.0118	CbGeAlD
Naproxen—PTGS1—female reproductive system—breast cancer	0.000155	0.0115	CbGeAlD
Naproxen—Ibuprofen—ABCC1—breast cancer	0.000154	0.0495	CrCbGaD
Naproxen—CYP1A2—endocrine gland—breast cancer	0.000151	0.0112	CbGeAlD
Naproxen—PTGS1—adrenal gland—breast cancer	0.000151	0.0112	CbGeAlD
Naproxen—PTGS2—female reproductive system—breast cancer	0.000148	0.011	CbGeAlD
Naproxen—PTGS2—adrenal gland—breast cancer	0.000144	0.0107	CbGeAlD
Naproxen—CYP2C9—endocrine gland—breast cancer	0.000143	0.0106	CbGeAlD
Naproxen—PTGS1—female gonad—breast cancer	0.000141	0.0104	CbGeAlD
Naproxen—PTGS2—bone marrow—breast cancer	0.00014	0.0103	CbGeAlD
Naproxen—Suprofen—PTGS1—breast cancer	0.000139	0.0447	CrCbGaD
Naproxen—Ketoprofen—CXCL8—breast cancer	0.000138	0.0445	CrCbGaD
Naproxen—Ibuprofen—CXCL8—breast cancer	0.000136	0.0438	CrCbGaD
Naproxen—PTGS2—female gonad—breast cancer	0.000135	0.00997	CbGeAlD
Naproxen—Nabumetone—PTGS2—breast cancer	0.000134	0.0433	CrCbGaD
Naproxen—PTGS1—endocrine gland—breast cancer	0.000131	0.0097	CbGeAlD
Naproxen—Carprofen—PTGS2—breast cancer	0.000128	0.0413	CrCbGaD
Naproxen—PTGS2—endocrine gland—breast cancer	0.000125	0.00927	CbGeAlD
Naproxen—Fenoprofen—PTGS1—breast cancer	0.000119	0.0385	CrCbGaD
Naproxen—PTGS1—lymph node—breast cancer	9.06e-05	0.0067	CbGeAlD
Naproxen—Indomethacin—PTGS1—breast cancer	8.82e-05	0.0284	CrCbGaD
Naproxen—PTGS2—lymph node—breast cancer	8.66e-05	0.00641	CbGeAlD
Naproxen—Suprofen—PTGS2—breast cancer	7.92e-05	0.0255	CrCbGaD
Naproxen—Flurbiprofen—PTGS1—breast cancer	7.79e-05	0.0251	CrCbGaD
Naproxen—Ketoprofen—PTGS1—breast cancer	7.05e-05	0.0227	CrCbGaD
Naproxen—Ibuprofen—PTGS1—breast cancer	6.94e-05	0.0224	CrCbGaD
Naproxen—Fenoprofen—PTGS2—breast cancer	6.83e-05	0.022	CrCbGaD
Naproxen—Fenoprofen—ALB—breast cancer	6.08e-05	0.0196	CrCbGaD
Naproxen—Indomethacin—PTGS2—breast cancer	5.04e-05	0.0162	CrCbGaD
Naproxen—Indomethacin—ALB—breast cancer	4.49e-05	0.0145	CrCbGaD
Naproxen—Flurbiprofen—PTGS2—breast cancer	4.46e-05	0.0144	CrCbGaD
Naproxen—Indomethacin—ABCB1—breast cancer	4.28e-05	0.0138	CrCbGaD
Naproxen—Ketoprofen—PTGS2—breast cancer	4.03e-05	0.013	CrCbGaD
Naproxen—Flurbiprofen—ALB—breast cancer	3.97e-05	0.0128	CrCbGaD
Naproxen—Ibuprofen—PTGS2—breast cancer	3.97e-05	0.0128	CrCbGaD
Naproxen—Ketoprofen—ALB—breast cancer	3.59e-05	0.0116	CrCbGaD
Naproxen—Ibuprofen—ALB—breast cancer	3.54e-05	0.0114	CrCbGaD
Naproxen—Ibuprofen—ABCB1—breast cancer	3.37e-05	0.0109	CrCbGaD
Naproxen—Headache—Fluorouracil—breast cancer	1.62e-05	0.000106	CcSEcCtD
Naproxen—Urinary tract disorder—Doxorubicin—breast cancer	1.62e-05	0.000106	CcSEcCtD
Naproxen—Oedema peripheral—Doxorubicin—breast cancer	1.62e-05	0.000106	CcSEcCtD
Naproxen—Gastrointestinal disorder—Docetaxel—breast cancer	1.61e-05	0.000106	CcSEcCtD
Naproxen—Connective tissue disorder—Doxorubicin—breast cancer	1.61e-05	0.000106	CcSEcCtD
Naproxen—Dyspnoea—Capecitabine—breast cancer	1.61e-05	0.000106	CcSEcCtD
Naproxen—Fatigue—Docetaxel—breast cancer	1.61e-05	0.000106	CcSEcCtD
Naproxen—Angiopathy—Epirubicin—breast cancer	1.61e-05	0.000106	CcSEcCtD
Naproxen—Urethral disorder—Doxorubicin—breast cancer	1.61e-05	0.000106	CcSEcCtD
Naproxen—Nausea—Irinotecan—breast cancer	1.61e-05	0.000105	CcSEcCtD
Naproxen—Nausea—Mitoxantrone—breast cancer	1.61e-05	0.000105	CcSEcCtD
Naproxen—Immune system disorder—Epirubicin—breast cancer	1.6e-05	0.000105	CcSEcCtD
Naproxen—Mediastinal disorder—Epirubicin—breast cancer	1.6e-05	0.000105	CcSEcCtD
Naproxen—Constipation—Docetaxel—breast cancer	1.6e-05	0.000105	CcSEcCtD
Naproxen—Pain—Docetaxel—breast cancer	1.6e-05	0.000105	CcSEcCtD
Naproxen—Dyspepsia—Capecitabine—breast cancer	1.59e-05	0.000105	CcSEcCtD
Naproxen—Chills—Epirubicin—breast cancer	1.59e-05	0.000104	CcSEcCtD
Naproxen—Arrhythmia—Epirubicin—breast cancer	1.59e-05	0.000104	CcSEcCtD
Naproxen—Visual impairment—Doxorubicin—breast cancer	1.58e-05	0.000104	CcSEcCtD
Naproxen—Asthenia—Paclitaxel—breast cancer	1.58e-05	0.000104	CcSEcCtD
Naproxen—Decreased appetite—Capecitabine—breast cancer	1.57e-05	0.000103	CcSEcCtD
Naproxen—Alopecia—Epirubicin—breast cancer	1.57e-05	0.000103	CcSEcCtD
Naproxen—Nausea—Gemcitabine—breast cancer	1.57e-05	0.000103	CcSEcCtD
Naproxen—Gastrointestinal disorder—Capecitabine—breast cancer	1.56e-05	0.000103	CcSEcCtD
Naproxen—Fatigue—Capecitabine—breast cancer	1.56e-05	0.000102	CcSEcCtD
Naproxen—Pruritus—Paclitaxel—breast cancer	1.56e-05	0.000102	CcSEcCtD
Naproxen—Vision blurred—Methotrexate—breast cancer	1.56e-05	0.000102	CcSEcCtD
Naproxen—Mental disorder—Epirubicin—breast cancer	1.56e-05	0.000102	CcSEcCtD
Naproxen—Erythema multiforme—Doxorubicin—breast cancer	1.55e-05	0.000102	CcSEcCtD
Naproxen—Pain—Capecitabine—breast cancer	1.55e-05	0.000102	CcSEcCtD
Naproxen—Constipation—Capecitabine—breast cancer	1.55e-05	0.000102	CcSEcCtD
Naproxen—Erythema—Epirubicin—breast cancer	1.55e-05	0.000101	CcSEcCtD
Naproxen—Malnutrition—Epirubicin—breast cancer	1.55e-05	0.000101	CcSEcCtD
Naproxen—Feeling abnormal—Docetaxel—breast cancer	1.54e-05	0.000101	CcSEcCtD
Naproxen—Nausea—Fluorouracil—breast cancer	1.54e-05	0.000101	CcSEcCtD
Naproxen—Eye disorder—Doxorubicin—breast cancer	1.54e-05	0.000101	CcSEcCtD
Naproxen—Ill-defined disorder—Methotrexate—breast cancer	1.53e-05	0.0001	CcSEcCtD
Naproxen—Tinnitus—Doxorubicin—breast cancer	1.53e-05	0.0001	CcSEcCtD
Naproxen—Gastrointestinal pain—Docetaxel—breast cancer	1.53e-05	0.0001	CcSEcCtD
Naproxen—Anaemia—Methotrexate—breast cancer	1.53e-05	0.0001	CcSEcCtD
Naproxen—Cardiac disorder—Doxorubicin—breast cancer	1.52e-05	0.0001	CcSEcCtD
Naproxen—Flatulence—Epirubicin—breast cancer	1.52e-05	9.99e-05	CcSEcCtD
Naproxen—Tension—Epirubicin—breast cancer	1.52e-05	9.95e-05	CcSEcCtD
Naproxen—Diarrhoea—Paclitaxel—breast cancer	1.51e-05	9.9e-05	CcSEcCtD
Naproxen—Nervousness—Epirubicin—breast cancer	1.5e-05	9.84e-05	CcSEcCtD
Naproxen—Feeling abnormal—Capecitabine—breast cancer	1.49e-05	9.78e-05	CcSEcCtD
Naproxen—Angiopathy—Doxorubicin—breast cancer	1.49e-05	9.77e-05	CcSEcCtD
Naproxen—Malaise—Methotrexate—breast cancer	1.49e-05	9.77e-05	CcSEcCtD
Naproxen—Muscle spasms—Epirubicin—breast cancer	1.49e-05	9.74e-05	CcSEcCtD
Naproxen—Immune system disorder—Doxorubicin—breast cancer	1.48e-05	9.73e-05	CcSEcCtD
Naproxen—Vertigo—Methotrexate—breast cancer	1.48e-05	9.73e-05	CcSEcCtD
Naproxen—Gastrointestinal pain—Capecitabine—breast cancer	1.48e-05	9.71e-05	CcSEcCtD
Naproxen—Mediastinal disorder—Doxorubicin—breast cancer	1.48e-05	9.71e-05	CcSEcCtD
Naproxen—Body temperature increased—Docetaxel—breast cancer	1.48e-05	9.69e-05	CcSEcCtD
Naproxen—Abdominal pain—Docetaxel—breast cancer	1.48e-05	9.69e-05	CcSEcCtD
Naproxen—Leukopenia—Methotrexate—breast cancer	1.48e-05	9.69e-05	CcSEcCtD
Naproxen—Chills—Doxorubicin—breast cancer	1.47e-05	9.67e-05	CcSEcCtD
Naproxen—Arrhythmia—Doxorubicin—breast cancer	1.47e-05	9.62e-05	CcSEcCtD
Naproxen—Dizziness—Paclitaxel—breast cancer	1.46e-05	9.57e-05	CcSEcCtD
Naproxen—Vision blurred—Epirubicin—breast cancer	1.46e-05	9.55e-05	CcSEcCtD
Naproxen—Alopecia—Doxorubicin—breast cancer	1.45e-05	9.52e-05	CcSEcCtD
Naproxen—Cough—Methotrexate—breast cancer	1.44e-05	9.45e-05	CcSEcCtD
Naproxen—Mental disorder—Doxorubicin—breast cancer	1.44e-05	9.44e-05	CcSEcCtD
Naproxen—Urticaria—Capecitabine—breast cancer	1.44e-05	9.43e-05	CcSEcCtD
Naproxen—Ill-defined disorder—Epirubicin—breast cancer	1.43e-05	9.4e-05	CcSEcCtD
Naproxen—Body temperature increased—Capecitabine—breast cancer	1.43e-05	9.39e-05	CcSEcCtD
Naproxen—Abdominal pain—Capecitabine—breast cancer	1.43e-05	9.39e-05	CcSEcCtD
Naproxen—Convulsion—Methotrexate—breast cancer	1.43e-05	9.38e-05	CcSEcCtD
Naproxen—Malnutrition—Doxorubicin—breast cancer	1.43e-05	9.38e-05	CcSEcCtD
Naproxen—Erythema—Doxorubicin—breast cancer	1.43e-05	9.38e-05	CcSEcCtD
Naproxen—Anaemia—Epirubicin—breast cancer	1.43e-05	9.37e-05	CcSEcCtD
Naproxen—Flatulence—Doxorubicin—breast cancer	1.41e-05	9.24e-05	CcSEcCtD
Naproxen—Arthralgia—Methotrexate—breast cancer	1.41e-05	9.22e-05	CcSEcCtD
Naproxen—Myalgia—Methotrexate—breast cancer	1.41e-05	9.22e-05	CcSEcCtD
Naproxen—Chest pain—Methotrexate—breast cancer	1.41e-05	9.22e-05	CcSEcCtD
Naproxen—Tension—Doxorubicin—breast cancer	1.4e-05	9.2e-05	CcSEcCtD
Naproxen—Vomiting—Paclitaxel—breast cancer	1.4e-05	9.2e-05	CcSEcCtD
Naproxen—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—breast cancer	1.4e-05	9.16e-05	CcSEcCtD
Naproxen—Malaise—Epirubicin—breast cancer	1.39e-05	9.14e-05	CcSEcCtD
Naproxen—Rash—Paclitaxel—breast cancer	1.39e-05	9.12e-05	CcSEcCtD
Naproxen—Dermatitis—Paclitaxel—breast cancer	1.39e-05	9.11e-05	CcSEcCtD
Naproxen—Discomfort—Methotrexate—breast cancer	1.39e-05	9.11e-05	CcSEcCtD
Naproxen—Nervousness—Doxorubicin—breast cancer	1.39e-05	9.11e-05	CcSEcCtD
Naproxen—Vertigo—Epirubicin—breast cancer	1.39e-05	9.11e-05	CcSEcCtD
Naproxen—Syncope—Epirubicin—breast cancer	1.39e-05	9.09e-05	CcSEcCtD
Naproxen—Leukopenia—Epirubicin—breast cancer	1.38e-05	9.07e-05	CcSEcCtD
Naproxen—Headache—Paclitaxel—breast cancer	1.38e-05	9.06e-05	CcSEcCtD
Naproxen—Hypersensitivity—Docetaxel—breast cancer	1.38e-05	9.04e-05	CcSEcCtD
Naproxen—Muscle spasms—Doxorubicin—breast cancer	1.37e-05	9.02e-05	CcSEcCtD
Naproxen—Palpitations—Epirubicin—breast cancer	1.37e-05	8.96e-05	CcSEcCtD
Naproxen—Confusional state—Methotrexate—breast cancer	1.36e-05	8.91e-05	CcSEcCtD
Naproxen—Loss of consciousness—Epirubicin—breast cancer	1.36e-05	8.91e-05	CcSEcCtD
Naproxen—Cough—Epirubicin—breast cancer	1.35e-05	8.84e-05	CcSEcCtD
Naproxen—Anaphylactic shock—Methotrexate—breast cancer	1.35e-05	8.84e-05	CcSEcCtD
Naproxen—Vision blurred—Doxorubicin—breast cancer	1.35e-05	8.84e-05	CcSEcCtD
Naproxen—Asthenia—Docetaxel—breast cancer	1.34e-05	8.8e-05	CcSEcCtD
Naproxen—Convulsion—Epirubicin—breast cancer	1.34e-05	8.78e-05	CcSEcCtD
Naproxen—Infection—Methotrexate—breast cancer	1.34e-05	8.78e-05	CcSEcCtD
Naproxen—Hypertension—Epirubicin—breast cancer	1.33e-05	8.75e-05	CcSEcCtD
Naproxen—Hypersensitivity—Capecitabine—breast cancer	1.33e-05	8.75e-05	CcSEcCtD
Naproxen—Ill-defined disorder—Doxorubicin—breast cancer	1.33e-05	8.7e-05	CcSEcCtD
Naproxen—Pruritus—Docetaxel—breast cancer	1.32e-05	8.68e-05	CcSEcCtD
Naproxen—Nervous system disorder—Methotrexate—breast cancer	1.32e-05	8.67e-05	CcSEcCtD
Naproxen—Anaemia—Doxorubicin—breast cancer	1.32e-05	8.67e-05	CcSEcCtD
Naproxen—Thrombocytopenia—Methotrexate—breast cancer	1.32e-05	8.65e-05	CcSEcCtD
Naproxen—Myalgia—Epirubicin—breast cancer	1.32e-05	8.63e-05	CcSEcCtD
Naproxen—Chest pain—Epirubicin—breast cancer	1.32e-05	8.63e-05	CcSEcCtD
Naproxen—Arthralgia—Epirubicin—breast cancer	1.32e-05	8.63e-05	CcSEcCtD
Naproxen—Anxiety—Epirubicin—breast cancer	1.31e-05	8.6e-05	CcSEcCtD
Naproxen—Nausea—Paclitaxel—breast cancer	1.31e-05	8.59e-05	CcSEcCtD
Naproxen—Skin disorder—Methotrexate—breast cancer	1.31e-05	8.59e-05	CcSEcCtD
Naproxen—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—breast cancer	1.31e-05	8.57e-05	CcSEcCtD
Naproxen—Hyperhidrosis—Methotrexate—breast cancer	1.3e-05	8.54e-05	CcSEcCtD
Naproxen—Discomfort—Epirubicin—breast cancer	1.3e-05	8.53e-05	CcSEcCtD
Naproxen—Asthenia—Capecitabine—breast cancer	1.3e-05	8.52e-05	CcSEcCtD
Naproxen—Malaise—Doxorubicin—breast cancer	1.29e-05	8.46e-05	CcSEcCtD
Naproxen—Dry mouth—Epirubicin—breast cancer	1.29e-05	8.44e-05	CcSEcCtD
Naproxen—Vertigo—Doxorubicin—breast cancer	1.28e-05	8.43e-05	CcSEcCtD
Naproxen—Anorexia—Methotrexate—breast cancer	1.28e-05	8.43e-05	CcSEcCtD
Naproxen—Syncope—Doxorubicin—breast cancer	1.28e-05	8.41e-05	CcSEcCtD
Naproxen—Pruritus—Capecitabine—breast cancer	1.28e-05	8.4e-05	CcSEcCtD
Naproxen—Leukopenia—Doxorubicin—breast cancer	1.28e-05	8.39e-05	CcSEcCtD
Naproxen—Diarrhoea—Docetaxel—breast cancer	1.28e-05	8.39e-05	CcSEcCtD
Naproxen—Confusional state—Epirubicin—breast cancer	1.27e-05	8.34e-05	CcSEcCtD
Naproxen—Palpitations—Doxorubicin—breast cancer	1.26e-05	8.29e-05	CcSEcCtD
Naproxen—Oedema—Epirubicin—breast cancer	1.26e-05	8.27e-05	CcSEcCtD
Naproxen—Anaphylactic shock—Epirubicin—breast cancer	1.26e-05	8.27e-05	CcSEcCtD
Naproxen—Hypotension—Methotrexate—breast cancer	1.26e-05	8.26e-05	CcSEcCtD
Naproxen—Loss of consciousness—Doxorubicin—breast cancer	1.26e-05	8.24e-05	CcSEcCtD
Naproxen—Infection—Epirubicin—breast cancer	1.25e-05	8.22e-05	CcSEcCtD
Naproxen—Cough—Doxorubicin—breast cancer	1.25e-05	8.18e-05	CcSEcCtD
Naproxen—Shock—Epirubicin—breast cancer	1.24e-05	8.14e-05	CcSEcCtD
Naproxen—Convulsion—Doxorubicin—breast cancer	1.24e-05	8.13e-05	CcSEcCtD
Naproxen—Diarrhoea—Capecitabine—breast cancer	1.24e-05	8.12e-05	CcSEcCtD
Naproxen—Nervous system disorder—Epirubicin—breast cancer	1.24e-05	8.11e-05	CcSEcCtD
Naproxen—Dizziness—Docetaxel—breast cancer	1.24e-05	8.11e-05	CcSEcCtD
Naproxen—Thrombocytopenia—Epirubicin—breast cancer	1.23e-05	8.1e-05	CcSEcCtD
Naproxen—Hypertension—Doxorubicin—breast cancer	1.23e-05	8.1e-05	CcSEcCtD
Naproxen—Tachycardia—Epirubicin—breast cancer	1.23e-05	8.07e-05	CcSEcCtD
Naproxen—Musculoskeletal discomfort—Methotrexate—breast cancer	1.23e-05	8.05e-05	CcSEcCtD
Naproxen—Skin disorder—Epirubicin—breast cancer	1.23e-05	8.03e-05	CcSEcCtD
Naproxen—Hyperhidrosis—Epirubicin—breast cancer	1.22e-05	8e-05	CcSEcCtD
Naproxen—Insomnia—Methotrexate—breast cancer	1.22e-05	7.99e-05	CcSEcCtD
Naproxen—Arthralgia—Doxorubicin—breast cancer	1.22e-05	7.98e-05	CcSEcCtD
Naproxen—Chest pain—Doxorubicin—breast cancer	1.22e-05	7.98e-05	CcSEcCtD
Naproxen—Myalgia—Doxorubicin—breast cancer	1.22e-05	7.98e-05	CcSEcCtD
Naproxen—Anxiety—Doxorubicin—breast cancer	1.21e-05	7.96e-05	CcSEcCtD
Naproxen—Paraesthesia—Methotrexate—breast cancer	1.21e-05	7.94e-05	CcSEcCtD
Naproxen—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—breast cancer	1.21e-05	7.93e-05	CcSEcCtD
Naproxen—Discomfort—Doxorubicin—breast cancer	1.2e-05	7.89e-05	CcSEcCtD
Naproxen—Anorexia—Epirubicin—breast cancer	1.2e-05	7.88e-05	CcSEcCtD
Naproxen—Dyspnoea—Methotrexate—breast cancer	1.2e-05	7.88e-05	CcSEcCtD
Naproxen—Somnolence—Methotrexate—breast cancer	1.2e-05	7.86e-05	CcSEcCtD
Naproxen—Dizziness—Capecitabine—breast cancer	1.2e-05	7.85e-05	CcSEcCtD
Naproxen—Dry mouth—Doxorubicin—breast cancer	1.19e-05	7.81e-05	CcSEcCtD
Naproxen—Vomiting—Docetaxel—breast cancer	1.19e-05	7.8e-05	CcSEcCtD
Naproxen—Dyspepsia—Methotrexate—breast cancer	1.19e-05	7.78e-05	CcSEcCtD
Naproxen—Rash—Docetaxel—breast cancer	1.18e-05	7.73e-05	CcSEcCtD
Naproxen—Hypotension—Epirubicin—breast cancer	1.18e-05	7.73e-05	CcSEcCtD
Naproxen—Dermatitis—Docetaxel—breast cancer	1.18e-05	7.73e-05	CcSEcCtD
Naproxen—Confusional state—Doxorubicin—breast cancer	1.18e-05	7.72e-05	CcSEcCtD
Naproxen—Decreased appetite—Methotrexate—breast cancer	1.17e-05	7.68e-05	CcSEcCtD
Naproxen—Headache—Docetaxel—breast cancer	1.17e-05	7.68e-05	CcSEcCtD
Naproxen—Oedema—Doxorubicin—breast cancer	1.17e-05	7.65e-05	CcSEcCtD
Naproxen—Anaphylactic shock—Doxorubicin—breast cancer	1.17e-05	7.65e-05	CcSEcCtD
Naproxen—Gastrointestinal disorder—Methotrexate—breast cancer	1.16e-05	7.63e-05	CcSEcCtD
Naproxen—Fatigue—Methotrexate—breast cancer	1.16e-05	7.62e-05	CcSEcCtD
Naproxen—Infection—Doxorubicin—breast cancer	1.16e-05	7.6e-05	CcSEcCtD
Naproxen—Pain—Methotrexate—breast cancer	1.15e-05	7.56e-05	CcSEcCtD
Naproxen—Vomiting—Capecitabine—breast cancer	1.15e-05	7.55e-05	CcSEcCtD
Naproxen—Musculoskeletal discomfort—Epirubicin—breast cancer	1.15e-05	7.54e-05	CcSEcCtD
Naproxen—Shock—Doxorubicin—breast cancer	1.15e-05	7.53e-05	CcSEcCtD
Naproxen—Nervous system disorder—Doxorubicin—breast cancer	1.14e-05	7.51e-05	CcSEcCtD
Naproxen—Thrombocytopenia—Doxorubicin—breast cancer	1.14e-05	7.49e-05	CcSEcCtD
Naproxen—Rash—Capecitabine—breast cancer	1.14e-05	7.49e-05	CcSEcCtD
Naproxen—Insomnia—Epirubicin—breast cancer	1.14e-05	7.48e-05	CcSEcCtD
Naproxen—Dermatitis—Capecitabine—breast cancer	1.14e-05	7.48e-05	CcSEcCtD
Naproxen—Tachycardia—Doxorubicin—breast cancer	1.14e-05	7.47e-05	CcSEcCtD
Naproxen—Headache—Capecitabine—breast cancer	1.13e-05	7.44e-05	CcSEcCtD
Naproxen—Skin disorder—Doxorubicin—breast cancer	1.13e-05	7.43e-05	CcSEcCtD
Naproxen—Paraesthesia—Epirubicin—breast cancer	1.13e-05	7.43e-05	CcSEcCtD
Naproxen—Hyperhidrosis—Doxorubicin—breast cancer	1.13e-05	7.4e-05	CcSEcCtD
Naproxen—Dyspnoea—Epirubicin—breast cancer	1.12e-05	7.37e-05	CcSEcCtD
Naproxen—Somnolence—Epirubicin—breast cancer	1.12e-05	7.35e-05	CcSEcCtD
Naproxen—Anorexia—Doxorubicin—breast cancer	1.11e-05	7.3e-05	CcSEcCtD
Naproxen—Nausea—Docetaxel—breast cancer	1.11e-05	7.28e-05	CcSEcCtD
Naproxen—Feeling abnormal—Methotrexate—breast cancer	1.11e-05	7.28e-05	CcSEcCtD
Naproxen—Dyspepsia—Epirubicin—breast cancer	1.11e-05	7.28e-05	CcSEcCtD
Naproxen—Gastrointestinal pain—Methotrexate—breast cancer	1.1e-05	7.23e-05	CcSEcCtD
Naproxen—Decreased appetite—Epirubicin—breast cancer	1.1e-05	7.19e-05	CcSEcCtD
Naproxen—Hypotension—Doxorubicin—breast cancer	1.09e-05	7.15e-05	CcSEcCtD
Naproxen—Gastrointestinal disorder—Epirubicin—breast cancer	1.09e-05	7.14e-05	CcSEcCtD
Naproxen—Fatigue—Epirubicin—breast cancer	1.09e-05	7.13e-05	CcSEcCtD
Naproxen—Constipation—Epirubicin—breast cancer	1.08e-05	7.07e-05	CcSEcCtD
Naproxen—Pain—Epirubicin—breast cancer	1.08e-05	7.07e-05	CcSEcCtD
Naproxen—Nausea—Capecitabine—breast cancer	1.08e-05	7.05e-05	CcSEcCtD
Naproxen—Urticaria—Methotrexate—breast cancer	1.07e-05	7.02e-05	CcSEcCtD
Naproxen—Abdominal pain—Methotrexate—breast cancer	1.07e-05	6.99e-05	CcSEcCtD
Naproxen—Body temperature increased—Methotrexate—breast cancer	1.07e-05	6.99e-05	CcSEcCtD
Naproxen—Musculoskeletal discomfort—Doxorubicin—breast cancer	1.06e-05	6.97e-05	CcSEcCtD
Naproxen—Insomnia—Doxorubicin—breast cancer	1.06e-05	6.92e-05	CcSEcCtD
Naproxen—Paraesthesia—Doxorubicin—breast cancer	1.05e-05	6.87e-05	CcSEcCtD
Naproxen—Dyspnoea—Doxorubicin—breast cancer	1.04e-05	6.82e-05	CcSEcCtD
Naproxen—Feeling abnormal—Epirubicin—breast cancer	1.04e-05	6.82e-05	CcSEcCtD
Naproxen—Somnolence—Doxorubicin—breast cancer	1.04e-05	6.8e-05	CcSEcCtD
Naproxen—Gastrointestinal pain—Epirubicin—breast cancer	1.03e-05	6.76e-05	CcSEcCtD
Naproxen—Dyspepsia—Doxorubicin—breast cancer	1.03e-05	6.74e-05	CcSEcCtD
Naproxen—Decreased appetite—Doxorubicin—breast cancer	1.01e-05	6.65e-05	CcSEcCtD
Naproxen—Gastrointestinal disorder—Doxorubicin—breast cancer	1.01e-05	6.61e-05	CcSEcCtD
Naproxen—Fatigue—Doxorubicin—breast cancer	1.01e-05	6.6e-05	CcSEcCtD
Naproxen—Urticaria—Epirubicin—breast cancer	1e-05	6.57e-05	CcSEcCtD
Naproxen—Constipation—Doxorubicin—breast cancer	9.98e-06	6.55e-05	CcSEcCtD
Naproxen—Pain—Doxorubicin—breast cancer	9.98e-06	6.55e-05	CcSEcCtD
Naproxen—Abdominal pain—Epirubicin—breast cancer	9.97e-06	6.54e-05	CcSEcCtD
Naproxen—Body temperature increased—Epirubicin—breast cancer	9.97e-06	6.54e-05	CcSEcCtD
Naproxen—Hypersensitivity—Methotrexate—breast cancer	9.93e-06	6.51e-05	CcSEcCtD
Naproxen—Asthenia—Methotrexate—breast cancer	9.67e-06	6.34e-05	CcSEcCtD
Naproxen—Feeling abnormal—Doxorubicin—breast cancer	9.62e-06	6.31e-05	CcSEcCtD
Naproxen—Gastrointestinal pain—Doxorubicin—breast cancer	9.54e-06	6.26e-05	CcSEcCtD
Naproxen—Pruritus—Methotrexate—breast cancer	9.54e-06	6.25e-05	CcSEcCtD
Naproxen—Hypersensitivity—Epirubicin—breast cancer	9.29e-06	6.09e-05	CcSEcCtD
Naproxen—Urticaria—Doxorubicin—breast cancer	9.27e-06	6.08e-05	CcSEcCtD
Naproxen—Abdominal pain—Doxorubicin—breast cancer	9.23e-06	6.05e-05	CcSEcCtD
Naproxen—Body temperature increased—Doxorubicin—breast cancer	9.23e-06	6.05e-05	CcSEcCtD
Naproxen—Diarrhoea—Methotrexate—breast cancer	9.22e-06	6.05e-05	CcSEcCtD
Naproxen—Asthenia—Epirubicin—breast cancer	9.05e-06	5.93e-05	CcSEcCtD
Naproxen—Pruritus—Epirubicin—breast cancer	8.92e-06	5.85e-05	CcSEcCtD
Naproxen—Dizziness—Methotrexate—breast cancer	8.91e-06	5.84e-05	CcSEcCtD
Naproxen—Diarrhoea—Epirubicin—breast cancer	8.63e-06	5.66e-05	CcSEcCtD
Naproxen—Hypersensitivity—Doxorubicin—breast cancer	8.6e-06	5.64e-05	CcSEcCtD
Naproxen—Vomiting—Methotrexate—breast cancer	8.57e-06	5.62e-05	CcSEcCtD
Naproxen—Rash—Methotrexate—breast cancer	8.5e-06	5.57e-05	CcSEcCtD
Naproxen—Dermatitis—Methotrexate—breast cancer	8.49e-06	5.57e-05	CcSEcCtD
Naproxen—Headache—Methotrexate—breast cancer	8.44e-06	5.54e-05	CcSEcCtD
Naproxen—Asthenia—Doxorubicin—breast cancer	8.37e-06	5.49e-05	CcSEcCtD
Naproxen—Dizziness—Epirubicin—breast cancer	8.34e-06	5.47e-05	CcSEcCtD
Naproxen—Pruritus—Doxorubicin—breast cancer	8.26e-06	5.41e-05	CcSEcCtD
Naproxen—Vomiting—Epirubicin—breast cancer	8.02e-06	5.26e-05	CcSEcCtD
Naproxen—Nausea—Methotrexate—breast cancer	8.01e-06	5.25e-05	CcSEcCtD
Naproxen—Diarrhoea—Doxorubicin—breast cancer	7.98e-06	5.24e-05	CcSEcCtD
Naproxen—Rash—Epirubicin—breast cancer	7.95e-06	5.22e-05	CcSEcCtD
Naproxen—Dermatitis—Epirubicin—breast cancer	7.95e-06	5.21e-05	CcSEcCtD
Naproxen—Headache—Epirubicin—breast cancer	7.9e-06	5.18e-05	CcSEcCtD
Naproxen—Dizziness—Doxorubicin—breast cancer	7.72e-06	5.06e-05	CcSEcCtD
Naproxen—Nausea—Epirubicin—breast cancer	7.49e-06	4.91e-05	CcSEcCtD
Naproxen—Vomiting—Doxorubicin—breast cancer	7.42e-06	4.87e-05	CcSEcCtD
Naproxen—Rash—Doxorubicin—breast cancer	7.36e-06	4.83e-05	CcSEcCtD
Naproxen—Dermatitis—Doxorubicin—breast cancer	7.35e-06	4.82e-05	CcSEcCtD
Naproxen—Headache—Doxorubicin—breast cancer	7.31e-06	4.79e-05	CcSEcCtD
Naproxen—Nausea—Doxorubicin—breast cancer	6.93e-06	4.55e-05	CcSEcCtD
Naproxen—PTGS2—Metabolism—NCOR1—breast cancer	2.54e-06	3.14e-05	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—HSP90AA1—breast cancer	2.53e-06	3.13e-05	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—ALB—breast cancer	2.53e-06	3.12e-05	CbGpPWpGaD
Naproxen—ALB—Metabolism—HSP90AA1—breast cancer	2.52e-06	3.11e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—ALDOA—breast cancer	2.51e-06	3.1e-05	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—MYC—breast cancer	2.51e-06	3.1e-05	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—TGFB1—breast cancer	2.5e-06	3.1e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—CYP17A1—breast cancer	2.5e-06	3.09e-05	CbGpPWpGaD
Naproxen—PTGS1—Metabolism of lipids and lipoproteins—PIK3CA—breast cancer	2.49e-06	3.08e-05	CbGpPWpGaD
Naproxen—AKR1C3—Disease—AKT1—breast cancer	2.48e-06	3.07e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—PTGS1—breast cancer	2.47e-06	3.06e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—ENO1—breast cancer	2.47e-06	3.06e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—CAV1—breast cancer	2.47e-06	3.05e-05	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—NCOA1—breast cancer	2.46e-06	3.05e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—breast cancer	2.46e-06	3.05e-05	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—EGFR—breast cancer	2.45e-06	3.03e-05	CbGpPWpGaD
Naproxen—ALB—Metabolism—NCOA1—breast cancer	2.45e-06	3.03e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—NCOA3—breast cancer	2.44e-06	3.01e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism of lipids and lipoproteins—ALB—breast cancer	2.43e-06	3.01e-05	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—GPX1—breast cancer	2.43e-06	3.01e-05	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—STK11—breast cancer	2.43e-06	3e-05	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—CYP19A1—breast cancer	2.43e-06	3e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—CYP2D6—breast cancer	2.42e-06	3e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—SLC2A2—breast cancer	2.42e-06	2.99e-05	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—NOS3—breast cancer	2.42e-06	2.99e-05	CbGpPWpGaD
Naproxen—ALB—Metabolism—CYP19A1—breast cancer	2.41e-06	2.99e-05	CbGpPWpGaD
Naproxen—ALB—Metabolism—STK11—breast cancer	2.41e-06	2.99e-05	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—CYP1A1—breast cancer	2.4e-06	2.98e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—breast cancer	2.39e-06	2.96e-05	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism—PIK3CB—breast cancer	2.39e-06	2.96e-05	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—ERCC2—breast cancer	2.38e-06	2.95e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—NCOA2—breast cancer	2.38e-06	2.94e-05	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—PIK3CG—breast cancer	2.37e-06	2.94e-05	CbGpPWpGaD
Naproxen—UGT2B7—Metabolism—PTEN—breast cancer	2.37e-06	2.93e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—CPT1A—breast cancer	2.37e-06	2.93e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—MTR—breast cancer	2.37e-06	2.93e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—ABCG2—breast cancer	2.37e-06	2.93e-05	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism—PTGS2—breast cancer	2.37e-06	2.93e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—HPGDS—breast cancer	2.32e-06	2.87e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—NOS2—breast cancer	2.32e-06	2.87e-05	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—KRAS—breast cancer	2.32e-06	2.87e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—HBA1—breast cancer	2.31e-06	2.86e-05	CbGpPWpGaD
Naproxen—ALB—Hemostasis—SRC—breast cancer	2.31e-06	2.86e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—FASN—breast cancer	2.31e-06	2.85e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—NOTCH1—breast cancer	2.3e-06	2.85e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—BCHE—breast cancer	2.3e-06	2.84e-05	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—breast cancer	2.28e-06	2.82e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—SLC5A5—breast cancer	2.27e-06	2.81e-05	CbGpPWpGaD
Naproxen—ALB—Metabolism of lipids and lipoproteins—PTEN—breast cancer	2.27e-06	2.8e-05	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—COMT—breast cancer	2.26e-06	2.79e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—ACHE—breast cancer	2.25e-06	2.79e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—GSTT1—breast cancer	2.25e-06	2.79e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—APC—breast cancer	2.25e-06	2.78e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—KIT—breast cancer	2.25e-06	2.78e-05	CbGpPWpGaD
Naproxen—ALB—Hemostasis—VEGFA—breast cancer	2.25e-06	2.78e-05	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—GSTP1—breast cancer	2.25e-06	2.78e-05	CbGpPWpGaD
Naproxen—ALB—Metabolism—COMT—breast cancer	2.24e-06	2.78e-05	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—MTHFR—breast cancer	2.24e-06	2.77e-05	CbGpPWpGaD
Naproxen—ALB—Metabolism—GSTP1—breast cancer	2.23e-06	2.76e-05	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—PIK3CB—breast cancer	2.23e-06	2.76e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—EGF—breast cancer	2.22e-06	2.75e-05	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—HMOX1—breast cancer	2.21e-06	2.74e-05	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—ITPR1—breast cancer	2.21e-06	2.73e-05	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—PTGS2—breast cancer	2.21e-06	2.73e-05	CbGpPWpGaD
Naproxen—ALB—Metabolism—HMOX1—breast cancer	2.2e-06	2.72e-05	CbGpPWpGaD
Naproxen—ALB—Metabolism—ITPR1—breast cancer	2.2e-06	2.72e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—SLC2A1—breast cancer	2.19e-06	2.71e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—NQO1—breast cancer	2.19e-06	2.71e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—breast cancer	2.15e-06	2.66e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—CYP3A4—breast cancer	2.14e-06	2.64e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—CYP17A1—breast cancer	2.13e-06	2.64e-05	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—PIK3CA—breast cancer	2.13e-06	2.63e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—breast cancer	2.13e-06	2.63e-05	CbGpPWpGaD
Naproxen—ALB—Hemostasis—MAPK3—breast cancer	2.13e-06	2.63e-05	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—ABCB1—breast cancer	2.13e-06	2.63e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—BRAF—breast cancer	2.11e-06	2.62e-05	CbGpPWpGaD
Naproxen—ALB—Metabolism—ABCB1—breast cancer	2.11e-06	2.62e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—ENO1—breast cancer	2.11e-06	2.61e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—PTGS1—breast cancer	2.11e-06	2.61e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—breast cancer	2.1e-06	2.6e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—CYP1B1—breast cancer	2.1e-06	2.6e-05	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—TYMS—breast cancer	2.09e-06	2.58e-05	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—PIK3CD—breast cancer	2.09e-06	2.58e-05	CbGpPWpGaD
Naproxen—AKR1C3—Metabolism—AKT1—breast cancer	2.08e-06	2.57e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism of lipids and lipoproteins—ALB—breast cancer	2.08e-06	2.57e-05	CbGpPWpGaD
Naproxen—ALB—Metabolism—TYMS—breast cancer	2.08e-06	2.57e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—CYP2D6—breast cancer	2.07e-06	2.56e-05	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—CAV1—breast cancer	2.07e-06	2.56e-05	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism—PTEN—breast cancer	2.06e-06	2.55e-05	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—GSTM1—breast cancer	2.06e-06	2.55e-05	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—NCOR1—breast cancer	2.06e-06	2.55e-05	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—PLA2G4A—breast cancer	2.06e-06	2.55e-05	CbGpPWpGaD
Naproxen—ALB—Hemostasis—TGFB1—breast cancer	2.06e-06	2.55e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—HSP90AA1—breast cancer	2.06e-06	2.55e-05	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—TP53—breast cancer	2.06e-06	2.55e-05	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—ALB—breast cancer	2.06e-06	2.55e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—AKT2—breast cancer	2.06e-06	2.55e-05	CbGpPWpGaD
Naproxen—ALB—Metabolism—PLA2G4A—breast cancer	2.05e-06	2.54e-05	CbGpPWpGaD
Naproxen—ALB—Metabolism—GSTM1—breast cancer	2.05e-06	2.54e-05	CbGpPWpGaD
Naproxen—ALB—Metabolism—NCOR1—breast cancer	2.05e-06	2.54e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—NCOA2—breast cancer	2.03e-06	2.51e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—NCOA1—breast cancer	2e-06	2.48e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—PIK3CD—breast cancer	1.98e-06	2.45e-05	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—GPX1—breast cancer	1.98e-06	2.45e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—CYP19A1—breast cancer	1.98e-06	2.44e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—STK11—breast cancer	1.98e-06	2.44e-05	CbGpPWpGaD
Naproxen—PTGS2—Metabolism of lipids and lipoproteins—PIK3CA—breast cancer	1.98e-06	2.44e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—FASN—breast cancer	1.97e-06	2.44e-05	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—HRAS—breast cancer	1.97e-06	2.44e-05	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—NOS3—breast cancer	1.97e-06	2.44e-05	CbGpPWpGaD
Naproxen—ALB—Metabolism—GPX1—breast cancer	1.97e-06	2.43e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—BCHE—breast cancer	1.96e-06	2.43e-05	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—CYP1A1—breast cancer	1.96e-06	2.42e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—SERPINE1—breast cancer	1.96e-06	2.42e-05	CbGpPWpGaD
Naproxen—ALB—Metabolism—CYP1A1—breast cancer	1.95e-06	2.41e-05	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—ERCC2—breast cancer	1.94e-06	2.4e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—SLC5A5—breast cancer	1.94e-06	2.4e-05	CbGpPWpGaD
Naproxen—ALB—Metabolism—ERCC2—breast cancer	1.93e-06	2.39e-05	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—PTEN—breast cancer	1.93e-06	2.38e-05	CbGpPWpGaD
Naproxen—ALB—Hemostasis—KRAS—breast cancer	1.91e-06	2.36e-05	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—IL6—breast cancer	1.89e-06	2.33e-05	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—PIK3CG—breast cancer	1.88e-06	2.33e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—SLC2A1—breast cancer	1.87e-06	2.32e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—NQO1—breast cancer	1.87e-06	2.32e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—NOS3—breast cancer	1.87e-06	2.31e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—breast cancer	1.85e-06	2.29e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—COMT—breast cancer	1.84e-06	2.27e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—breast cancer	1.83e-06	2.27e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—GSTP1—breast cancer	1.83e-06	2.26e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—CYP3A4—breast cancer	1.83e-06	2.26e-05	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—MTHFR—breast cancer	1.82e-06	2.26e-05	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—PIK3CB—breast cancer	1.82e-06	2.25e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—breast cancer	1.82e-06	2.25e-05	CbGpPWpGaD
Naproxen—ALB—Metabolism—MTHFR—breast cancer	1.81e-06	2.24e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—HMOX1—breast cancer	1.8e-06	2.23e-05	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—PTGS2—breast cancer	1.8e-06	2.23e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—ITPR1—breast cancer	1.8e-06	2.23e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—CYP1B1—breast cancer	1.8e-06	2.22e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—MDM2—breast cancer	1.77e-06	2.19e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—RAF1—breast cancer	1.76e-06	2.18e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—HSP90AA1—breast cancer	1.76e-06	2.18e-05	CbGpPWpGaD
Naproxen—ALB—Hemostasis—PIK3CA—breast cancer	1.76e-06	2.17e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—ERBB2—breast cancer	1.75e-06	2.16e-05	CbGpPWpGaD
Naproxen—AKR1C3—Signaling Pathways—AKT1—breast cancer	1.74e-06	2.15e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—ABCB1—breast cancer	1.73e-06	2.14e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—PIK3CB—breast cancer	1.72e-06	2.13e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—MTOR—breast cancer	1.72e-06	2.13e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—CD4—breast cancer	1.72e-06	2.13e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—NCOA1—breast cancer	1.71e-06	2.12e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—TYMS—breast cancer	1.7e-06	2.1e-05	CbGpPWpGaD
Naproxen—ALB—Hemostasis—TP53—breast cancer	1.7e-06	2.1e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—STK11—breast cancer	1.69e-06	2.09e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—CYP19A1—breast cancer	1.69e-06	2.09e-05	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—CAV1—breast cancer	1.68e-06	2.08e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—NCOR1—breast cancer	1.68e-06	2.08e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—PLA2G4A—breast cancer	1.68e-06	2.08e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—GSTM1—breast cancer	1.68e-06	2.08e-05	CbGpPWpGaD
Naproxen—UGT2B7—Metabolism—PIK3CA—breast cancer	1.67e-06	2.07e-05	CbGpPWpGaD
Naproxen—ALB—Metabolism—CAV1—breast cancer	1.67e-06	2.07e-05	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—PIK3CD—breast cancer	1.66e-06	2.05e-05	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—ALB—breast cancer	1.63e-06	2.02e-05	CbGpPWpGaD
Naproxen—ALB—Hemostasis—HRAS—breast cancer	1.62e-06	2.01e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—CDKN1B—breast cancer	1.62e-06	2e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—GPX1—breast cancer	1.61e-06	1.99e-05	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—breast cancer	1.61e-06	1.99e-05	CbGpPWpGaD
Naproxen—ALB—Metabolism of lipids and lipoproteins—PIK3CA—breast cancer	1.6e-06	1.98e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—CYP1A1—breast cancer	1.59e-06	1.97e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—breast cancer	1.58e-06	1.96e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—ERCC2—breast cancer	1.58e-06	1.95e-05	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—PTEN—breast cancer	1.57e-06	1.94e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—COMT—breast cancer	1.57e-06	1.94e-05	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—NOS3—breast cancer	1.56e-06	1.93e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—GSTP1—breast cancer	1.56e-06	1.93e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—HMOX1—breast cancer	1.54e-06	1.91e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—ITPR1—breast cancer	1.54e-06	1.9e-05	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—PIK3CG—breast cancer	1.53e-06	1.9e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—CTNNB1—breast cancer	1.53e-06	1.89e-05	CbGpPWpGaD
Naproxen—ALB—Metabolism—PIK3CG—breast cancer	1.52e-06	1.89e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—CDKN1A—breast cancer	1.49e-06	1.85e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—PTEN—breast cancer	1.49e-06	1.84e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—MTHFR—breast cancer	1.48e-06	1.84e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—ABCB1—breast cancer	1.48e-06	1.83e-05	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism—PIK3CA—breast cancer	1.46e-06	1.8e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—TYMS—breast cancer	1.45e-06	1.8e-05	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—PIK3CB—breast cancer	1.44e-06	1.79e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—PLA2G4A—breast cancer	1.44e-06	1.78e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—NCOR1—breast cancer	1.44e-06	1.78e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—GSTM1—breast cancer	1.44e-06	1.78e-05	CbGpPWpGaD
Naproxen—ALB—Hemostasis—AKT1—breast cancer	1.43e-06	1.77e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—SRC—breast cancer	1.38e-06	1.71e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—GPX1—breast cancer	1.37e-06	1.7e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—CAV1—breast cancer	1.37e-06	1.69e-05	CbGpPWpGaD
Naproxen—UGT2B7—Metabolism—AKT1—breast cancer	1.37e-06	1.69e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—CYP1A1—breast cancer	1.36e-06	1.68e-05	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—PIK3CA—breast cancer	1.36e-06	1.68e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—ERCC2—breast cancer	1.35e-06	1.67e-05	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—PIK3CD—breast cancer	1.35e-06	1.67e-05	CbGpPWpGaD
Naproxen—ALB—Metabolism—PIK3CD—breast cancer	1.34e-06	1.66e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—STAT3—breast cancer	1.33e-06	1.65e-05	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—ALB—breast cancer	1.33e-06	1.65e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—breast cancer	1.31e-06	1.62e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—MAPK3—breast cancer	1.27e-06	1.57e-05	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—NOS3—breast cancer	1.27e-06	1.57e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—MTHFR—breast cancer	1.27e-06	1.57e-05	CbGpPWpGaD
Naproxen—ALB—Metabolism—NOS3—breast cancer	1.26e-06	1.57e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—PIK3CG—breast cancer	1.25e-06	1.54e-05	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—PTEN—breast cancer	1.25e-06	1.54e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—MYC—breast cancer	1.24e-06	1.53e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—TGFB1—breast cancer	1.23e-06	1.53e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—EGFR—breast cancer	1.21e-06	1.5e-05	CbGpPWpGaD
Naproxen—SLCO1A2—Metabolism—AKT1—breast cancer	1.19e-06	1.47e-05	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—PIK3CB—breast cancer	1.17e-06	1.45e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—CAV1—breast cancer	1.17e-06	1.45e-05	CbGpPWpGaD
Naproxen—ALB—Metabolism—PIK3CB—breast cancer	1.17e-06	1.44e-05	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—PTGS2—breast cancer	1.16e-06	1.44e-05	CbGpPWpGaD
Naproxen—ALB—Metabolism—PTGS2—breast cancer	1.16e-06	1.43e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—KRAS—breast cancer	1.14e-06	1.41e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—breast cancer	1.12e-06	1.38e-05	CbGpPWpGaD
Naproxen—UGT1A1—Metabolism—AKT1—breast cancer	1.11e-06	1.37e-05	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—PIK3CA—breast cancer	1.11e-06	1.37e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—PIK3CD—breast cancer	1.1e-06	1.36e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—ALB—breast cancer	1.08e-06	1.34e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—PIK3CG—breast cancer	1.07e-06	1.32e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—PIK3CA—breast cancer	1.05e-06	1.3e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—NOS3—breast cancer	1.04e-06	1.28e-05	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—PTEN—breast cancer	1.01e-06	1.26e-05	CbGpPWpGaD
Naproxen—ALB—Metabolism—PTEN—breast cancer	1.01e-06	1.25e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—HRAS—breast cancer	9.72e-07	1.2e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—PIK3CB—breast cancer	9.56e-07	1.18e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—PTGS2—breast cancer	9.47e-07	1.17e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—PIK3CD—breast cancer	9.37e-07	1.16e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—IL6—breast cancer	9.3e-07	1.15e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—ALB—breast cancer	9.25e-07	1.14e-05	CbGpPWpGaD
Naproxen—PTGS1—Metabolism—AKT1—breast cancer	9.05e-07	1.12e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—NOS3—breast cancer	8.85e-07	1.09e-05	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—PIK3CA—breast cancer	8.8e-07	1.09e-05	CbGpPWpGaD
Naproxen—PTGS2—Disease—AKT1—breast cancer	8.58e-07	1.06e-05	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—PTEN—breast cancer	8.26e-07	1.02e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—PIK3CB—breast cancer	8.17e-07	1.01e-05	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—PTGS2—breast cancer	8.09e-07	1e-05	CbGpPWpGaD
Naproxen—PTGS2—Metabolism—AKT1—breast cancer	7.19e-07	8.89e-06	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—PIK3CA—breast cancer	7.16e-07	8.86e-06	CbGpPWpGaD
Naproxen—ALB—Metabolism—PIK3CA—breast cancer	7.12e-07	8.81e-06	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—PTEN—breast cancer	7.06e-07	8.73e-06	CbGpPWpGaD
Naproxen—CYP2C8—Metabolism—AKT1—breast cancer	5.85e-07	7.24e-06	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—PIK3CA—breast cancer	5.83e-07	7.21e-06	CbGpPWpGaD
Naproxen—ALB—Metabolism—AKT1—breast cancer	5.81e-07	7.19e-06	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—PIK3CA—breast cancer	4.98e-07	6.16e-06	CbGpPWpGaD
Naproxen—CYP2C9—Metabolism—AKT1—breast cancer	4.76e-07	5.89e-06	CbGpPWpGaD
Naproxen—CYP1A2—Metabolism—AKT1—breast cancer	4.07e-07	5.03e-06	CbGpPWpGaD
